Wird geladen...
Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
There is no standard therapy for refractory acute myeloid leukemia (AML), but several salvage therapies are available (National Comprehensive Cancer Network [NCCN], 2018). Recently, there have been major developments in the treatment of AML focusing on the development of targeted and novel therapies...
Gespeichert in:
| Veröffentlicht in: | J Adv Pract Oncol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Harborside Press LLC
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7779565/ https://ncbi.nlm.nih.gov/pubmed/33457062 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.5.7 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|